Revisions of precautions for various drugs in Japan

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2024年 / 2007卷 / 1期

关键词：

D O I：

10.1007/s40278-024-58567-z

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：7 / 7

相关论文

共 50 条

[1] Revisions of precautions for COVID-19 vaccines and other drugs in Japan
Reactions Weekly, 2021, 1867 (1) : 8 - 8
[2] Revisions of precautions in Japan in November 2022
Reactions Weekly, 2022, 1934 (1) : 4 - 4
[3] Revisions of precautions for preparations containing acetaminophen in Japan
Reactions Weekly, 2023, 1984 (1) : 4 - 4
[4] PMDA revises precautions for three drugs in Japan
Reactions Weekly, 2021, 1879 (1) : 4 - 4
[5] Japan's PMDA revises precautions for various products
Reactions Weekly, 2015, 1572 (1) : 6 - 6
[6] PMDA regulatory update on approval of new drugs and revisions of precautions; approval of talazoparib tosilate for prostate and breast cancer, and luspatercept for myelodysplastic syndrome in Japan
Matsumura, Noriomi
Mandai, Masaki
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (05) : 493 - 494
[7] PMDA regulatory update on approval of new drugs and revisions of precautions; approval of talazoparib tosilate for prostate and breast cancer, and luspatercept for myelodysplastic syndrome in Japan
Noriomi Matsumura
Masaki Mandai
International Journal of Clinical Oncology, 2024, 29 : 493 - 494
[8] Japan PMDA's recommends revised precautions for various products
Reactions Weekly, 2020, 1806 (1) : 5 - 5
[9] PMDA revisions of precautions: June 2024
Reactions Weekly, 2024, 2013 (1) : 9 - 9
[10] Revisions of precautions and ADRs for monoclonal antibodies
Reactions Weekly, 2021, 1862 (1) : 5 - 5

← 1 2 3 4 5 →